Ian G Mills

List of Publications by Citations

185 papers	14,116 citations	48 h-index	117 g-index
245 ext. papers	16,485 ext. citations	8 avg, IF	6.04 L-index

#	Paper	IF	Citations
185	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). *Autophagy*, **2016**, 12, 1-222	10.2	3838
184	BAR domains as sensors of membrane curvature: the amphiphysin BAR structure. *Science*, **2004**, 303, 495-9	33.3	1353
183	Curvature of clathrin-coated pits driven by epsin. *Nature*, **2002**, 419, 361-6	50.4	798
182	The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. *EMBO Journal*, **2011**, 30, 2719-33	13	423
181	GTPase activity of dynamin and resulting conformation change are essential for endocytosis. *Nature*, **2001**, 410, 231-5	50.4	378
180	Principles for the post-GWAS functional characterization of cancer risk loci. *Nature Genetics*, **2011**, 43, 513-8	36.3	326
179	The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man. *Cancer Cell*, **2013**, 23, 35-47	24.3	282
178	ER stress-mediated autophagy promotes Myc-dependent transformation and tumor growth. *Journal of Clinical Investigation*, **2012**, 122, 4621-34	15.9	279
177	COP and clathrin-coated vesicle budding: different pathways, common approaches. *Current Opinion in Cell Biology*, **2004**, 16, 379-91	9	240
176	New androgen receptor genomic targets show an interaction with the ETS1 transcription factor. *EMBO Reports*, **2007**, 8, 871-8	6.5	219
175	EpsinR: an AP1/clathrin interacting protein involved in vesicle trafficking. *Journal of Cell Biology*, **2003**, 160, 213-22	7.3	206
174	Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. *EMBO Journal*, **2011**, 30, 3019-27	13	203
173	Role of the AP2 beta-appendage hub in recruiting partners for clathrin-coated vesicle assembly. *PLoS Biology*, **2006**, 4, e262	9.7	197
172	O-GlcNAc transferase integrates metabolic pathways to regulate the stability of c-MYC in human prostate cancer cells. *Cancer Research*, **2013**, 73, 5277-87	10.1	191
171	Clathrin adaptor epsinR is required for retrograde sorting on early endosomal membranes. *Developmental Cell*, **2004**, 6, 525-38	10.2	191
170	Involvement of the endosomal autoantigen EEA1 in homotypic fusion of early endosomes. *Current Biology*, **1998**, 8, 881-4	6.3	189
169	Structural basis for the nuclear import of the human androgen receptor. *Journal of Cell Science*, **2008**, 121, 957-68	5.3	164

168	Evolving nature of the AP2 alpha-appendage hub during clathrin-coated vesicle endocytosis. *EMBO Journal*, **2004**, 23, 4371-83	13	154
167	Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study. *EBioMedicine*, **2015**, 2, 1133-44	8.8	143
166	Thiol isomerases negatively regulate the cellular shedding activity of ADAM17. *Biochemical Journal*, **2010**, 428, 439-50	3.8	135
165	Exome sequencing of prostate cancer supports the hypothesis of independent tumour origins. *European Urology*, **2013**, 63, 347-53	10.2	115
164	Maintaining and reprogramming genomic androgen receptor activity in prostate cancer. *Nature Reviews Cancer*, **2014**, 14, 187-98	31.3	111
163	Endosomal localization and receptor dynamics determine tyrosine phosphorylation of hepatocyte growth factor-regulated tyrosine kinase substrate. *Molecular and Cellular Biology*, **2000**, 20, 7685-92	4.8	110
162	Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer. *Nature Communications*, **2017**, 8, 374	17.4	99
161	IRE1ΕXBP1s pathway promotes prostate cancer by activating c-MYC signaling. *Nature Communications*, **2019**, 10, 323	17.4	93
160	The importance of DNA methylation in prostate cancer development. *Journal of Steroid Biochemistry and Molecular Biology*, **2017**, 166, 1-15	5.1	85
159	Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. *BMJ, The*, **2018**, 360, j5757	5.9	85
158	Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesis. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 11252-7	11.5	82
157	The mitochondrial and autosomal mutation landscapes of prostate cancer. *European Urology*, **2013**, 63, 702-8	10.2	80
156	Somatic Genomics and Clinical Features of Lung Adenocarcinoma: A Retrospective Study. *PLoS Medicine*, **2016**, 13, e1002162	11.6	78
155	The developing role of receptors and adaptors. *Nature Reviews Cancer*, **2006**, 6, 403-9	31.3	76
154	Localization of polymorphic N-acetyltransferase (NAT2) in tissues of inbred mice. *Pharmacogenetics and Genomics*, **1997**, 7, 121-30		74
153	Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer. *Cell Reports*, **2017**, 19, 2045-2059	10.6	72
152	Gene regulatory mechanisms underpinning prostate cancer susceptibility. *Nature Genetics*, **2016**, 48, 387-97	36.3	72
151	Modulation of intracellular calcium homeostasis blocks autophagosome formation. *Autophagy*, **2013**, 9, 1475-90	10.2	70

150	LYRIC/AEG-1 is targeted to different subcellular compartments by ubiquitinylation and intrinsic nuclear localization signals. *Clinical Cancer Research*, **2009**, 15, 3003-13	12.9	67
149	UAP1 is overexpressed in prostate cancer and is protective against inhibitors of N-linked glycosylation. *Oncogene*, **2015**, 34, 3744-50	9.2	65
148	c-Myc Antagonises the Transcriptional Activity of the Androgen Receptor in Prostate Cancer Affecting Key Gene Networks. *EBioMedicine*, **2017**, 18, 83-93	8.8	63
147	PIAS1 is increased in human prostate cancer and enhances proliferation through inhibition of p21. *American Journal of Pathology*, **2012**, 180, 2097-107	5.8	61
146	ChIPping away at gene regulation. *EMBO Reports*, **2008**, 9, 337-43	6.5	61
145	Alterations in beta-catenin expression and localization in prostate cancer. *Prostate*, **2008**, 68, 1196-205	4.2	61
144	Huntingtin interacting protein 1 modulates the transcriptional activity of nuclear hormone receptors. *Journal of Cell Biology*, **2005**, 170, 191-200	7.3	59
143	Autophagic bulk sequestration of cytosolic cargo is independent of LC3, but requires GABARAPs. *Experimental Cell Research*, **2015**, 333, 21-38	4.2	55
142	Divergent androgen regulation of unfolded protein response pathways drives prostate cancer. *EMBO Molecular Medicine*, **2015**, 7, 788-801	12	55
141	The role of glycans in the development and progression of prostate cancer. *Nature Reviews Urology*, **2016**, 13, 324-33	5.5	53
140	Molecular subtyping of primary prostate cancer reveals specific and shared target genes of different ETS rearrangements. *Neoplasia*, **2012**, 14, 600-11	6.4	52
139	Tumor necrosis factor receptor expression and signaling in renal cell carcinoma. *American Journal of Pathology*, **2010**, 177, 943-54	5.8	50
138	The androgen receptor controls expression of the cancer-associated sTn antigen and cell adhesion through induction of ST6GalNAc1 in prostate cancer. *Oncotarget*, **2015**, 6, 34358-74	3.3	49
137	Nuclear ARRB1 induces pseudohypoxia and cellular metabolism reprogramming in prostate cancer. *EMBO Journal*, **2014**, 33, 1365-82	13	48
136	Regulation of endosome fusion. *Molecular Membrane Biology*, **1999**, 16, 73-9	3.4	48
135	The Early Effects of Rapid Androgen Deprivation on Human Prostate Cancer. *European Urology*, **2016**, 70, 214-8	10.2	47
134	Glycosylation is an Androgen-Regulated Process Essential for Prostate Cancer Cell Viability. *EBioMedicine*, **2016**, 8, 103-116	8.8	46
133	Promoter methylation correlates with reduced Smad4 expression in advanced prostate cancer. *Prostate*, **2008**, 68, 661-74	4.2	46

132	Inhibition of endosome fusion by wortmannin persists in the presence of activated Rab5. *Molecular Biology of the Cell*, **1998**, 9, 323-32	3.5	46
131	Inhibition of O-GlcNAc transferase activity reprograms prostate cancer cell metabolism. *Oncotarget*, **2016**, 7, 12464-76	3.3	46
130	HES6 drives a critical AR transcriptional programme to induce castration-resistant prostate cancer through activation of an E2F1-mediated cell cycle network. *EMBO Molecular Medicine*, **2014**, 6, 651-61	12	45
129	Androgen-regulated metabolism and biosynthesis in prostate cancer. *Endocrine-Related Cancer*, **2014**, 21, T57-66	5.7	44
128	Myc-dependent purine biosynthesis affects nucleolar stress and therapy response in prostate cancer. *Oncotarget*, **2015**, 6, 12587-602	3.3	42
127	Lipid degradation promotes prostate cancer cell survival. *Oncotarget*, **2017**, 8, 38264-38275	3.3	41
126	Shared common variants in prostate cancer and blood lipids. *International Journal of Epidemiology*, **2014**, 43, 1205-14	7.8	39
125	The interplay between clathrin-coated vesicles and cell signalling. *Seminars in Cell and Developmental Biology*, **2007**, 18, 459-70	7.5	39
124	Elevated NCOR1 disrupts a network of dietary-sensing nuclear receptors in bladder cancer cells. *Carcinogenesis*, **2009**, 30, 449-56	4.6	37
123	A new look towards BAC-based array CGH through a comprehensive comparison with oligo-based array CGH. *BMC Genomics*, **2007**, 8, 84	4.5	36
122	N-linked glycosylation supports cross-talk between receptor tyrosine kinases and androgen receptor. *PLoS ONE*, **2013**, 8, e65016	3.7	35
121	The induction of core pluripotency master regulators in cancers defines poor clinical outcomes and treatment resistance. *Oncogene*, **2019**, 38, 4412-4424	9.2	33
120	Novel role of androgens in mitochondrial fission and apoptosis. *Molecular Cancer Research*, **2011**, 9, 1067-77	6.7	32
119	High OGT activity is essential for MYC-driven proliferation of prostate cancer cells. *Theranostics*, **2019**, 9, 2183-2197	12.1	31
118	Salt-inducible kinase 2 regulates mitotic progression and transcription in prostate cancer. *Molecular Cancer Research*, **2015**, 13, 620-635	6.6	31
117	The molecular signature of the stroma response in prostate cancer-induced osteoblastic bone metastasis highlights expansion of hematopoietic and prostate epithelial stem cell niches. *PLoS ONE*, **2014**, 9, e114530	3.7	31
116	HNF1B variants associate with promoter methylation and regulate gene networks activated in prostate and ovarian cancer. *Oncotarget*, **2016**, 7, 74734-74746	3.3	31
115	Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model. *British Journal of Cancer*, **2020**, 123, 1089-1100	8.7	30

114	Disseminated tumor cells and their prognostic significance in nonmetastatic prostate cancer patients. *International Journal of Cancer*, **2013**, 133, 149-55	7.5	30
113	Abundant genetic overlap between blood lipids and immune-mediated diseases indicates shared molecular genetic mechanisms. *PLoS ONE*, **2015**, 10, e0123057	3.7	30
112	CTCF modulates Estrogen Receptor function through specific chromatin and nuclear matrix interactions. *Nucleic Acids Research*, **2016**, 44, 10588-10602	20.1	29
111	Dual transcriptome of the immediate neutrophil and Candida albicans interplay. *BMC Genomics*, **2017**, 18, 696	4.5	27
110	Validation of a Metastatic Assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy. *Annals of Oncology*, **2018**, 29, 215-222	10.3	27
109	Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target. *Journal of the National Cancer Institute*, **2016**, 108,	9.7	27
108	Slug-dependent upregulation of L1CAM is responsible for the increased invasion potential of pancreatic cancer cells following long-term 5-FU treatment. *PLoS ONE*, **2015**, 10, e0123684	3.7	27
107	Cell cycle-coupled expansion of AR activity promotes cancer progression. *Oncogene*, **2017**, 36, 1655-1668	8.2	26
106	The ETS family member GABPmodulates androgen receptor signalling and mediates an aggressive phenotype in prostate cancer. *Nucleic Acids Research*, **2014**, 42, 6256-69	20.1	26
105	Meta-analysis of prostate cancer gene expression data identifies a novel discriminatory signature enriched for glycosylating enzymes. *BMC Medical Genomics*, **2014**, 7, 513	3.7	26
104	Genome-wide analysis of AR binding and comparison with transcript expression in primary human fetal prostate fibroblasts and cancer associated fibroblasts. *Molecular and Cellular Endocrinology*, **2018**, 471, 1-14	4.4	25
103	A role for neurotensin in bicalutamide resistant prostate cancer cells. *Prostate*, **2007**, 67, 190-202	4.2	25
102	Drivers of AR indifferent anti-androgen resistance in prostate cancer cells. *Scientific Reports*, **2019**, 9, 13786	4.9	24
101	Glucocorticoid receptor and Klf4 co-regulate anti-inflammatory genes in keratinocytes. *Molecular and Cellular Endocrinology*, **2015**, 412, 281-9	4.4	24
100	Pro-neural transcription factors as cancer markers. *BMC Medical Genomics*, **2008**, 1, 17	3.7	24
99	Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer. *European Journal of Medicinal Chemistry*, **2018**, 160, 108-119	6.8	24
98	Bromodomain protein 4 discriminates tissue-specific super-enhancers containing disease-specific susceptibility loci in prostate and breast cancer. *BMC Genomics*, **2017**, 18, 270	4.5	22
97	Low Expression of miR-424-3p is Highly Correlated with Clinical Failure in Prostate Cancer. *Scientific Reports*, **2019**, 9, 10662	4.9	22

96	Identification of shared genetic variants between schizophrenia and lung cancer. *Scientific Reports*, **2018**, 8, 674	4.9	21
95	Time-varying analysis of electrodermal activity during exercise. *PLoS ONE*, **2018**, 13, e0198328	3.7	21
94	The cancer-associated cell migration protein TSPAN1 is under control of androgens and its upregulation increases prostate cancer cell migration. *Scientific Reports*, **2017**, 7, 5249	4.9	21
93	Macroautophagic cargo sequestration assays. *Methods*, **2015**, 75, 25-36	4.6	21
92	Mining Human Prostate Cancer Datasets: The "camcAPP" Shiny App. *EBioMedicine*, **2017**, 17, 5-6	8.8	20
91	Solitary and repetitive binding motifs for the AP2 complex alpha-appendage in amphiphysin and other accessory proteins. *Journal of Biological Chemistry*, **2008**, 283, 5099-109	5.4	19
90	The Oncogene Metadherin Interacts with the Known Splicing Proteins YTHDC1, Sam68 and T-STAR and Plays a Novel Role in Alternative mRNA Splicing. *Cancers*, **2019**, 11,	6.6	17
89	A Four-Group Urine Risk Classifier for Predicting Outcome in Prostate Cancer Patients. *BJU International*, **2019**, 124, 609	5.6	17
88	Inhibition of O-GlcNAc Transferase Renders Prostate Cancer Cells Dependent on CDK9. *Molecular Cancer Research*, **2020**, 18, 1512-1521	6.6	17
87	Bromodomain-containing proteins in prostate cancer. *Molecular and Cellular Endocrinology*, **2018**, 462, 31-40	4.4	17
86	Mapping protein-DNA interactions using ChIP-sequencing. *Methods in Molecular Biology*, **2012**, 809, 157-73	1.4	17
85	Nuclear trafficking and functions of endocytic proteins implicated in oncogenesis. *Traffic*, **2009**, 10, 1209-20	5.7	17
84	The Adrenergic Receptor Is a Molecular Switch for Neuroendocrine Transdifferentiation of Prostate Cancer Cells. *Molecular Cancer Research*, **2019**, 17, 2154-2168	6.6	16
83	A differential protein solubility approach for the depletion of highly abundant proteins in plasma using ammonium sulfate. *Analyst, The*, **2015**, 140, 8109-17	5	16
82	Chromatin binding by the androgen receptor in prostate cancer. *Molecular and Cellular Endocrinology*, **2012**, 360, 44-51	4.4	16
81	miR-191 promotes radiation resistance of prostate cancer through interaction with RXRA. *Cancer Letters*, **2020**, 473, 107-117	9.9	16
80	ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer. *Cancer Research*, **2021**, 81, 1704-1718	10.1	16
79	Genetics of lipid metabolism in prostate cancer. *Nature Genetics*, **2018**, 50, 169-171	36.3	15

78	Changes of 5-hydroxymethylcytosine distribution during myeloid and lymphoid differentiation of CD34+ cells. *Epigenetics and Chromatin*, **2016**, 9, 21	5.8	15
77	Quantitative ELISAs for serum soluble LHCGR and hCG-LHCGR complex: potential diagnostics in first trimester pregnancy screening for stillbirth, Down Syndrome, preterm delivery and preeclampsia. *Reproductive Biology and Endocrinology*, **2012**, 10, 113	5	15
76	Molecular Subgroup of Primary Prostate Cancer Presenting with Metastatic Biology. *European Urology*, **2017**, 72, 509-518	10.2	14
75	A Genetic Risk Score to Personalize Prostate Cancer Screening, Applied to Population Data. *Cancer Epidemiology Biomarkers and Prevention*, **2020**, 29, 1731-1738	4	14
74	Polygenic hazard score is associated with prostate cancer in multi-ethnic populations. *Nature Communications*, **2021**, 12, 1236	17.4	14
73	Propagation of human prostate tissue from induced pluripotent stem cells. *Stem Cells Translational Medicine*, **2020**, 9, 734-745	6.9	13
72	Calcium Channel Blocker Use and Risk of Prostate Cancer by TMPRSS2:ERG Gene Fusion Status. *Prostate*, **2017**, 77, 282-290	4.2	13
71	Global identification of androgen response elements. *Methods in Molecular Biology*, **2011**, 776, 255-73	1.4	13
70	CDK9 Inhibition Induces a Metabolic Switch that Renders Prostate Cancer Cells Dependent on Fatty Acid Oxidation. *Neoplasia*, **2019**, 21, 713-720	6.4	12
69	Genetic Sharing with Cardiovascular Disease Risk Factors and Diabetes Reveals Novel Bone Mineral Density Loci. *PLoS ONE*, **2015**, 10, e0144531	3.7	12
68	A reciprocal feedback between the PDZ binding kinase and androgen receptor drives prostate cancer. *Oncogene*, **2019**, 38, 1136-1150	9.2	12
67	Nuclear translocation and functions of growth factor receptors. *Seminars in Cell and Developmental Biology*, **2012**, 23, 165-71	7.5	11
66	AURKA overexpression accompanies dysregulation of DNA-damage response genes in invasive urothelial cell carcinoma. *Cell Cycle*, **2008**, 7, 3525-33	4.7	11
65	Vascular normalisation as the stepping stone into tumour microenvironment transformation. *British Journal of Cancer*, **2021**, 125, 324-336	8.7	11
64	The Unfolded Protein Response: A Novel Therapeutic Target for Poor Prognostic Mutant Colorectal Cancer. *Molecular Cancer Therapeutics*, **2018**, 17, 1280-1290	6.1	10
63	Cardioprotective effects of dietary rapamycin on adult female C57BLKS/J-Lepr mice. *Annals of the New York Academy of Sciences*, **2018**, 1418, 106-117	6.5	10
62	First trimester maternal serum alpha-fetoprotein is not raised in pregnancies with open spina bifida. *Prenatal Diagnosis*, **2014**, 34, 168-71	3.2	10
61	First trimester detection of trisomy 16 using combined biochemical and ultrasound screening. *Prenatal Diagnosis*, **2014**, 34, 291-5	3.2	10

60	Putting chromatin immunoprecipitation into context. *Journal of Cellular Biochemistry*, **2009**, 107, 19-29	4.7	10
59	Chromatin immunoprecipitation (ChIP) methodology and readouts. *Methods in Molecular Biology*, **2009**, 505, 123-37	1.4	10
58	Human blood-based exposure levels of persistent organic pollutant (POP) mixtures antagonise androgen receptor transactivation and translocation. *Environment International*, **2019**, 132, 105083	12.9	9
57	Pleiotropic Analysis of Lung Cancer and Blood Triglycerides. *Journal of the National Cancer Institute*, **2016**, 108,	9.7	9
56	Derivation and Application of Molecular Signatures to Prostate Cancer: Opportunities and Challenges. *Cancers*, **2021**, 13,	6.6	9
55	Genetic factors influencing prostate cancer risk in Norwegian men. *Prostate*, **2018**, 78, 186-192	4.2	9
54	Independence of HIF1a and androgen signaling pathways in prostate cancer. *BMC Cancer*, **2020**, 20, 469	4.8	8
53	A PHASE 2, 8-WEEK, MULTI-CENTER, RANDOMIZED DOUBLE- BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY EVALUATING THE EFFICACY, TOLERABILITY AND SAFETY OF [S,S] - REBOXETINE (PNU-165442G) FOR STRESS URINARY INCONTINENCE IN WOMEN. *Journal of Urology*, **2008**, 179, 569-570	2.5	8
52	Clathrin is spindle-associated but not essential for mitosis. *PLoS ONE*, **2008**, 3, e3115	3.7	8
51	O-GlcNAc Transferase - An Auxiliary Factor or a Full-blown Oncogene?. *Molecular Cancer Research*, **2021**, 19, 555-564	6.6	8
50	A gene signature associated with PTEN activation defines good prognosis intermediate risk prostate cancer cases. *Journal of Pathology: Clinical Research*, **2018**, 4, 103-113	5.3	7
49	Inhibition of O-GlcNAc transferase activates tumor-suppressor gene expression in tamoxifen-resistant breast cancer cells. *Scientific Reports*, **2020**, 10, 16992	4.9	7
48	African-specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer. *International Journal of Cancer*, **2021**, 148, 99-105	7.5	7
47	Endosomal signaling and oncogenesis. *Methods in Enzymology*, **2014**, 535, 179-200	1.7	6
46	Terminal and progenitor lineage-survival oncogenes as cancer markers. *Trends in Molecular Medicine*, **2008**, 14, 486-94	11.5	6
45	EVALUATION OF THE SENSITIVITY OF URETHRAL PRESSURE REFLECTOMETRY (UPR) AND URETHRAL PRESSURE PROFILOMETRY (UPP) TO DETECT PHARMACOLOGICAL AUGMENTATION OF URETHRAL PRESSURE, USING [S,S]-REBOXETINE. *Journal of Urology*, **2008**, 179, 521-522	2.5	6
44	Identification and Validation of Leucine-rich α-2-glycoprotein 1 as a Noninvasive Biomarker for Improved Precision in Prostate Cancer Risk Stratification. *European Urology Open Science*, **2020**, 21, 51-60	8.9	6
43	A feedback loop between the androgen receptor and 6-phosphogluconate dehydrogenase (6PGD) drives prostate cancer growth. *ELife*, **2021**, 10,	8.9	6

42	The effect of sample size on polygenic hazard models for prostate cancer. *European Journal of Human Genetics*, **2020**, 28, 1467-1475	5.3	5
41	HOXB13, RFX6 and prostate cancer risk. *Nature Genetics*, **2014**, 46, 94-5	36.3	5
40	The impact of HIV infection and antiretroviral therapy on the predicted risk of Down syndrome. *Prenatal Diagnosis*, **2014**, 34, 121-7	3.2	5
39	The impact of transcription on metabolism in prostate and breast cancers. *Endocrine-Related Cancer* , **2018**, 25, R435-R452	5.7	5
38	Association of maternal serum PAPP-A levels, nuchal translucency and crown-rump length in first trimester with adverse pregnancy outcomes: retrospective cohort study. *Prenatal Diagnosis*, **2017**, 37, 705-711	3.2	4
37	Mapping Protein-DNA Interactions Using ChIP-exo and Illumina-Based Sequencing. *Methods in Molecular Biology*, **2016**, 1443, 119-37	1.4	4
36	Methodology for the at-home collection of urine samples for prostate cancer detection. *BioTechniques*, **2020**, 68, 65-71	2.5	4
35	A Systematic Review of Prostate Cancer Heterogeneity: Understanding the Clonal Ancestry of Multifocal Disease. *European Urology Oncology*, **2021**, 4, 358-369	6.7	4
34	Modulating the unfolded protein response with ONC201 to impact on radiation response in prostate cancer cells. *Scientific Reports*, **2021**, 11, 4252	4.9	4
33	Prenatal screening for Down syndrome in twin pregnancies: Estimates of screening performance based on 61 affected and 7302 unaffected twin pregnancies. *Prenatal Diagnosis*, **2018**, 38, 1079-1085	3.2	4
32	Inhibition of CDK9 activity compromises global splicing in prostate cancer cells. *RNA Biology*, **2021**, 1-8	4.8	4
31	Sjögren syndrome/scleroderma autoantigen 1 is a direct Tankyrase binding partner in cancer cells. *Communications Biology*, **2020**, 3, 123	6.7	3
30	Studying N-linked glycosylation of receptor tyrosine kinases. *Methods in Molecular Biology*, **2015**, 1233, 103-9	1.4	3
29	Common genetic and clinical risk factors: association with fatal prostate cancer in the Cohort of Swedish Men. *Prostate Cancer and Prostatic Diseases*, **2021**, 24, 845-851	6.2	3
28	Human-Based Exposure Levels of Perfluoroalkyl Acids May Induce Harmful Effects to Health by Disrupting Major Components of Androgen Receptor Signalling In Vitro. *Exposure and Health*, **2020**, 12, 527-538	8.8	3
27	Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer. *Prostate Cancer and Prostatic Diseases*, **2021**, 24, 532-541	6.2	3
26	The Interplay Between Prostate Cancer Genomics, Metabolism, and the Epigenome: Perspectives and Future Prospects. *Frontiers in Oncology*, **2021**, 11, 704353	5.3	3
25	Detailed Molecular and Immune Marker Profiling of Archival Prostate Cancer Samples Reveals an Inverse Association between TMPRSS2:ERG Fusion Status and Immune Cell Infiltration. *Journal of Molecular Diagnostics*, **2020**, 22, 652-669	5.1	2

24	Using the fluorescent properties of STO-609 as a tool to assist structure-function analyses of recombinant CaMKK2. *Biochemical and Biophysical Research Communications*, **2016**, 476, 102-7	3.4	2
23	Taking risks with translational research. *Science Translational Medicine*, **2010**, 2, 24cm10	17.5	2
22	The role of the androgen receptor as a driver and mitigator of cellular stress. *Journal of Molecular Endocrinology*, **2020**, 65, R19-R33	4.5	2
21	Investigating Radiotherapy Response in a Novel Syngeneic Model of Prostate Cancer. *Cancers*, **2020**, 12,	6.6	2
20	Data for the co-expression and purification of human recombinant CaMKK2 in complex with calmodulin in Escherichia coli. *Data in Brief*, **2016**, 8, 733-40	1.2	2
19	Ductal adenocarcinoma of the prostate: A systematic review and meta-analysis of incidence, presentation, prognosis, and management.. *BJUI Compass*, **2021**, 2, 13-23	0.9	2
18	Principles for the post-GWAS functional characterisation of risk loci. *Nature Precedings*, **2010**,		1
17	Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. *EMBO Journal*, **2012**, 31, 1617-1617	13	1
16	A genetic risk score to personalize prostate cancer screening, applied to population data.. *Journal of Clinical Oncology*, **2019**, 37, 181-181	2.2	1
15	CaMKK2 facilitates Golgi-associated vesicle trafficking to sustain cancer cell proliferation. *Cell Death and Disease*, **2021**, 12, 1040	9.8	1
14	Polygenic hazard score is associated with prostate cancer in multi-ethnic populations		1
13	African-specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer		1
12	Clinical and functional characterization of CXCR1/CXCR2 biology in the relapse and radiotherapy resistance of primary PTEN-deficient prostate carcinoma. *NAR Cancer*, **2020**, 2, zcaa012	5.2	1
11	Transcript analysis of commercial prostate cancer risk stratification panels in hard-to-predict grade group 2-4 prostate cancers. *Prostate*, **2021**, 81, 368-376	4.2	1
10	Tumour irradiation combined with vascular-targeted photodynamic therapy enhances antitumour effects in pre-clinical prostate cancer. *British Journal of Cancer*, **2021**, 125, 534-546	8.7	1
9	The spatial landscape of clonal somatic mutations in benign and malignant tissue		1
8	Single-cell ATAC and RNA sequencing reveal pre-existing and persistent subpopulations of cells associated with relapse of prostate cancer		1
7	DDIS-16. ONC201 IN COMBINATION WITH RADIATION EXHIBITS SYNERGISTIC EFFICACY IN HIGH GRADE GLIOMAS AND OTHER ADVANCED CANCERS. *Neuro-Oncology*, **2018**, 20, vi72-vi72	1	1

6	Hyperpolarised C-MRI identifies the emergence of a glycolytic cell population within intermediate-risk human prostate cancer.. *Nature Communications*, **2022**, 13, 466	17.4	0
5	The Effect of AR Overexpression on Androgen Signaling in Prostate Cancer **2013**, 187-200		0
4	IGF-1R nuclear import and recruitment to chromatin involves both alpha and beta subunits. *Discover Oncology*, **2021**, 12, 13		0
3	In Vitro Techniques **2006**, 201-378		
2	Predicting long-term results with circulating tumor cells in patients with de novo androgen sensitive prostate cancer treated with hTERT peptides vaccine.. *Journal of Clinical Oncology*, **2020**, 38, 98-98	2.2	
1	Common genetic and clinical risk factors: Association with fatal prostate cancer in the Cohort of Swedish Men.. *Journal of Clinical Oncology*, **2021**, 39, 65-65	2.2	